journal article·2018-11-05Open access

The effect of SiO2/Au core–shell nanoparticles on breast cancer cell’s radiotherapy

Ghazal Darfarin, Roya Salehi, Effat Alizadeh, Behnam Nasiri Motlagh, Abolfazl Akbarzadeh, Alireza Farajollahi

Abstract

Introduction Recently it has been shown that radiation dose enhancement could be achievable in radiotherapy using nanoparticles (NPs). In this study, evaluation was made to determine efficiency of gold-silica shell-core NP in megavoltage irradiation of MCF7 breath cancer cells. Materials and methods Gold-silicon oxide shell-core NPs were obtained by conjugation of gold NP with amine or thiol functionalized silica NPs (AuN@SiO2 and AuS@SiO2). Cellular uptake and cytotoxicity of NPs were examined by fluorescent microscopy and MTT assay, respectively. MCF-7 breast cancer cells were treated with both NPs and irradiation was made with X-ray energies of 6 and 18 MV to the absorbed dose of 2, 4 and 8 Gy using Simense linear accelerator. The efficiency of radiation therapy was then evaluated by MTT and Brdu assay, DAPI staining and cell cycle analysis. Results TEM images indicated that synthesized NPs had average diameter of 25 nm. Cellular uptake demonstrated that the internalization of AuS@SiO2 and AuN@SiO2 NPs amounted to 18% and 34%, 3 h post treatment, respectively. Nontoxicity of prepared NPs on MCF-7 cells was proved by MTT and Brdu assays as well as DAPI staining and cell cycle studies. The highest enhancement in radiation dose was observed in the cells that irradiated with radiation energy of 18 MV and absorbed of 8 Gy at NPs concentration of 200 ppm. The Brdu findings revealed that the cytotoxicity and apoptosis on MCF-7 cells are dose dependent with a significantly more death in AuN@SiO2 (amine) exposed cells (p < .05). Analysis also revealed interruption in cell cycle by demonstrating lack of cells, in S phase in amine treated cells (AuN@SiO2) at given dose of 8 Gy using 18 MV X-ray in comparison to thiol treated cells. Conclusions Based on the results of the study it can be concluded that the gold-silicon oxide shell-core NPs could play an effective role in radiotherapy of MCF-7 breast cancer cells.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Radiation Therapy and Dosimetry · Radiation Shielding Materials Analysis · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran;

Department of Medical Nanotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Science, Tabriz, Iran;

Department of Medical Biotechnology, Faculty of Advanced Medical Science, Tabriz University of Medical Sciences, Tabriz, Iran;

Department of Radiation Oncology, Tabriz Valiasr Hospital, Tabriz, Iran;

Tuberculosis and Lung Disease Research Center of Tabriz, Tabriz University of Medical Sciences, Tabriz, Iran;

Department of Chemical Engineering, Northeastern University, Boston, MA, USA;

Department of Medical Physics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran;

Department of Radiotherapy, Imam Reza University Hospital, Tabriz University of Medical sciences, Tabriz, Iran

Funding

Tabriz University of Medical Sciences

References (23)

Show source-provided references
1. Harirchi I · Asian Pac J Cancer Prev · 2004 · 5 · 24
2. 10.3109/21691401.2015.102962510.3109/21691401.2015.1029625 ↗
3. 10.1016/j.msec.2014.10.06210.1016/j.msec.2014.10.062 ↗
4. 10.2217/nnm.14.5510.2217/nnm.14.55 ↗
5. Kwatra D · Translat Cancer Res · 2013 · 2 · 330
6. 10.3109/1073119920911973410.3109/10731199209119734 ↗
7. 10.1080/21691401.2018.143984310.1080/21691401.2018.1439843 ↗
8. 10.1021/nl050127s10.1021/nl050127s ↗
9. Klein S · J Nanomater Mol Nanotechnol · 2014 · 2 · 002
10. 10.3109/09553002.2014.88810410.3109/09553002.2014.888104 ↗
11. 10.1088/0031-9155/49/18/N0310.1088/0031-9155/49/18/N03 ↗
12. 10.1016/j.radonc.2013.04.00410.1016/j.radonc.2013.04.004 ↗
13. 10.1080/21691401.2017.134794110.1080/21691401.2017.1347941 ↗
14. 10.1080/0955300005015163710.1080/09553000050151637 ↗
15. 10.1166/jnn.2006.1797010.1166/jnn.2006.17970 ↗
16. 10.1088/0031-9155/56/15/00110.1088/0031-9155/56/15/001 ↗
17. 10.1080/15685551.2013.84047510.1080/15685551.2013.840475 ↗
18. 10.1039/C5RA22784D10.1039/C5RA22784D ↗
19. 10.1039/C6NJ04107H10.1039/C6NJ04107H ↗
20. 10.1039/C6RA23213B10.1039/C6RA23213B ↗
21. 10.1111/bcpt.1282210.1111/bcpt.12822 ↗
22. 10.18632/oncotarget.318810.18632/oncotarget.3188 ↗
23. 10.2147/IJN.S8298010.2147/IJN.S82980 ↗